[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,004,948
  • Shares Outstanding, K 39,348
  • Annual Sales, $ 726,410 K
  • Annual Income, $ 7,030 K
  • EBIT $ 81 M
  • EBITDA $ 170 M
  • 60-Month Beta 0.27
  • Price/Sales 1.38
  • Price/Cash Flow 6.60
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 64.48% (+6.11%)
  • Historical Volatility 23.95%
  • IV Percentile 50%
  • IV Rank 28.30%
  • IV High 128.93% on 03/16/26
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 3) 0.30 (1.18%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 1,109
  • Open Int (30-Day) 1,037
  • Expected Range 24.84 to 25.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.27
  • Number of Estimates 1
  • High Estimate $0.27
  • Low Estimate $0.27
  • Prior Year $0.47
  • Growth Rate Est. (year over year) -42.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.00 +13.59%
on 06/22/26
26.66 -6.26%
on 07/07/26
+2.00 (+8.70%)
since 06/12/26
3-Month
21.92 +14.01%
on 05/20/26
27.13 -7.89%
on 05/01/26
+1.24 (+5.22%)
since 04/14/26
52-Week
18.80 +32.93%
on 01/20/26
27.64 -9.59%
on 09/03/25
+1.68 (+7.21%)
since 07/14/25

Most Recent Stories

More News
PHARMACORP ANNOUNCES CLOSING OF C$11.5 MILLION BOUGHT DEAL PUBLIC OFFERING

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

PCRX : 24.95 (-2.31%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 24.95 (-2.31%)
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management  Across Outpatient Settings --  BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX),...

PCRX : 24.95 (-2.31%)
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing...

PCRX : 24.95 (-2.31%)
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting

BRISBANE, Calif. , June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain...

PCRX : 24.95 (-2.31%)
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum

PCRX : 24.95 (-2.31%)
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"

PCRX : 24.95 (-2.31%)
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees

BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid...

PCRX : 24.95 (-2.31%)
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE

PCRX : 24.95 (-2.31%)
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees

Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees...

PCRX : 24.95 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 26.50
2nd Resistance Point 26.20
1st Resistance Point 25.87
Last Price 24.95
1st Support Level 25.23
2nd Support Level 24.93
3rd Support Level 24.60

See More

52-Week High 27.64
Last Price 24.95
Fibonacci 61.8% 24.26
Fibonacci 50% 23.22
Fibonacci 38.2% 22.18
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.